Psoriasis drug apremilast tested in kids for safety

NCT ID NCT06088199

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the safety of the drug apremilast (Otezla) in 51 children and teens aged 6 to 17 with mild to moderate plaque psoriasis. Participants take the drug as an oral tablet, and researchers monitor for side effects, growth, and development. The goal is to see if this existing psoriasis treatment is safe for younger patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apremilast (Otezla)
What this could lead to: If successful, this could confirm that apremilast is a safe option for managing psoriasis in children and teens.
What could go wrong: This is a small, open-label study without a placebo group, so results may not prove effectiveness. Side effects are possible, and long-term safety in growing children is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Affiliated Dermatology

Scottsdale, Arizona, 85255, United States
Austin Institute for Clinical Research

Pflugerville, Texas, 78660, United States
Avance Clinical Trials

Laguna Niguel, California, 92677, United States
Boeson Research

Missoula, Montana, 59804, United States
California Dermatology Institute

Thousand Oaks, California, 91320, United States
Ciocca Dermatology

Miami, Florida, 33173, United States
Clear Dermatology

Scottsdale, Arizona, 85255, United States
Clinical Science Institute

Santa Monica, California, 90404, United States
Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, 46250, United States
Dermatology Research Center of Oklahoma, PLLC

Tulsa, Oklahoma, 74132, United States
Dermatology and Skin Cancer Center of Lees Summit

Lee's Summit, Missouri, 64064, United States
Empire Dermatology

East Syracuse, New York, 13057, United States
Endeavor Health Clinical Trials Center

Skokie, Illinois, 60077, United States
Frontier Derm Partners

Mill Creek, Washington, 98012, United States
Great Lakes Research Group Inc- Sheffield

Bay City, Michigan, 48706, United States
Henry Ford Medical Center - New Center One

Detroit, Michigan, 48202, United States
Hightower Clinical LLC

Oklahoma City, Oklahoma, 73120, United States
Johnson Dermatology Clinic

Fort Smith, Arkansas, 72916, United States
MedDerm Associates

San Diego, California, 92103, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
OptiSkin Medical

New York, New York, 10029, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Pediatric Skin Research LLC

Coral Gables, Florida, 33146, United States
Southern Indiana Clinical Trials

New Albany, Indiana, 47150, United States
State University of New York, Downstate Medical Center

Manhasset, New York, 11030, United States
Stride Clinical Research LLC

Sugar Land, Texas, 77479, United States
Studies in Dermatology LLC

Cypress, Texas, 77429, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of California Irvine

Orange, California, 92868, United States
University of South Florida

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.